This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wellbrock, C. Articles by Marais, R. Search for Related Content PubMed PubMed Citation Articles by Wellbrock, C. Articles by Marais, R.

^V599EB-RAF is an Oncogene in Melanocytes

¹ Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, The Institute of Cancer Research, London, United Kingdom, and ² Gene and Oncogene Targeting Team, The Institute of Cancer Research, Sutton, Surrey, United Kingdom

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The oncogenic version of B-RAF, ^V599EB-RAF, is found in approximately 70% of human melanomas. However, the role that this oncogene plays in melanoma is unclear because ^V559EB-RAF is also found in approximately 80% of benign nevi. We have examined the role of oncogenic B-RAF in the early stages of melanoma by expressing ^V599EB-RAF in cultured melanocytes. In these cells, ^V599EB-RAF induced constitutive mitogen activated ERK-activating kinase (MEK) and extracellular signal-regulated kinase (ERK) signaling, 12-O-tetradecanoylphorbol-13-acetate-independent growth, and tumorigenicity in nude mice. Intriguingly, in RAS-transformed melanocytes, B-RAF depletion did not block MEK-ERK signaling or cell cycle progression. Similarly, B-RAF depletion blocked MEK-ERK signaling in human melanoma cells harboring oncogenic B-RAF, but not in melanoma cells harboring oncogenic RAS. Thus, although B-RAF can act as a potent oncogene in the early stages of melanoma by signaling through MEK and ERK, it is not required for this signaling in RAS-transformed melanocytes due to innate redundancy within the pathway. These findings have important implications for future therapeutic strategies.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
The RAS proteins regulate cell proliferation, survival, and differentiation by activating a number of effector proteins, including the RalGDS exchange factors, the phosphatidylinositol 3'-kinases, and the three RAF protein kinases (A-RAF, B-RAF, and C-RAF). Once activated, RAF proteins stimulate a signaling cascade involving the MEK and extracellular signal-regulated kinase (ERK) protein kinases. For many years, RAS signaling has been implicated in initiation and progression of melanoma. Approximately 15–20% of human melanomas have mutations in RAS genes (1 , 2) , but RAS activation in melanocytes is not sufficient to induce melanoma in mouse models unless the cell cycle progression inhibitor p16^INK4A is also deleted (3) . Importantly, the majority of sporadic melanomas are p16^INK4A negative (4) , and germ-line mutations in p16^INK4A lead to a dramatically increased lifetime risk of melanoma (4) .

Although RAS clearly plays a role in human melanoma, its importance has recently been superseded by the discovery that the RAS effector B-RAF is mutated in approximately 70% of cutaneous melanomas (5, 6, 7) . However, like RAS, oncogenic B-RAF is not sufficient to induce melanoma because B-RAF mutations are also found in 80% of nevi, which are benign melanocytic lesions (6 , 8) . The most frequent mutation in B-RAF (80%) is a glutamic acid for valine substitution at position 599, which produces a protein that has elevated kinase activity in vitro and induces constitutive activation of ERK (5) . Importantly, ERK activity is elevated in the majority of melanoma cell lines (7) , and elevated ERK signaling appears to be required for melanocyte proliferation in culture (9, 10, 11) . This, together with the observation that B-RAF and RAS mutations are mutually exclusive, suggests that RAS induces ERK activation in a B-RAF-dependent manner and that these oncogenes transform melanocytes through a common mechanism. Oncogenic RAS transforms cultured mouse and human melanocytes, suggesting a role in melanoma initiation (12 , 13) , but it is not known whether B-RAF can do the same. In view of its high rate of mutation in melanoma, it is essential to investigate whether B-RAF can transform melanocytes to allow us to determine whether it has a role in initiation of melanoma.

Here we show that ^V599EB-RAF stimulates constitutive ERK activity and transforms melan-a cells, immortalized melanocytes that possess all of the characteristics of normal melanocytes (14) . However, B-RAF is not essential for ERK activation in RAS-transformed melanocytes. Similar results were obtained in human melanoma cell lines expressing oncogenic B-RAF or oncogenic RAS, demonstrating the physiological significance of our results. These data show that ^V599EB-RAF is an important melanocyte oncogene but that wild-type B-RAF (^WTB-RAF) is not required for ERK signaling in RAS-transformed melanocytes or in melanoma cells harboring oncogenic RAS because there is innate redundancy in this pathway.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
Cell Culture.
The melan-a cells (14) were maintained in RPMI 1640 (Gibco) containing 10% FCS, 200 nM 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma), and 300 pM cholera toxin (Sigma). For generation of stable B-RAF- or ^V599EB-RAF-expressing clones, 4 x 10⁴ cells per 24-well plate were transfected with pMCEF-B-RAF or pMCEF-^V599EB-RAF using LipofectAMINE (Invitrogen) as described previously (11) . TPA (200 nM) was added to the medium for cells transfected with either the empty vector or ^WTB-RAF but not to cells transfected with ^V599EB-RAF. Individual clones were isolated and subcloned after 3 weeks. Human melanoma cell lines were maintained in DMEM (CHL, WM266-4, and SK-MEL-2) or RPMI 1640 (WM35) containing 10% FCS. Melanocytes transformed by ^G12VHa-RAS (LTRras cells; Ref. 12 ) and activated MEK (MEKEE cells) were cultured in RPMI 1640/10% FCS.

Thymidine Incorporation and Soft Agar Growth.
A total of 4 x 10⁴ melan-a cells were seeded per well on a 24-well plate. When present, 10 µM U0126 was added 24 h before the cells were harvested. After 20 h, [³H]thymidine (0.4 µCi/ml) was added, and after 4 h, incorporated [³H]thymidine was quantified by liquid scintillation counting. For long-term growth experiments, cells were seeded at 1 x 10⁶ cells/10-cm dish in medium containing either 10% FCS or 10% FCS + 100 nM TPA. Cells were counted every 3 days and replated at 1 x 10⁶ cells/10-cm dish. For the anchorage-independent growth assay, 1 x 10⁴ cells were suspended in 0.45% low melting point (LMP)-agarose in RPMI 1640/10% FCS and overlaid onto 0.9% LMP-agarose/RPMI 1640 in a 6-cm dish. Before colonies were stained with crystal violet, 1 ml of fresh medium was added twice a week for 3 weeks.

Cell Lysis, Western Blotting, Antibodies, and Inhibitors.
Cells were lysed in 50 mM Tris (pH 7.5), 150 mM NaCl, 0.5% NP40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na₃VO₄, 10 µg/ml leupeptin, and 10 µg/ml aprotinin for 20 min at 4°C. Proteins were separated by SDS-PAGE, and Western blot analysis was performed following standard protocols using the following antibodies: B-RAF (F-7; Santa Cruz Biotechnology); C-RAF (M40091.G; Anogen); phospho-ERK (MAPK-YT; Sigma); 9E10 (15) ; ERK2 (#122; Ref. 16 ); and phospho-MEK (New England Biolabs). U0126 was from Promega, and the RAF inhibitor BAY 43-9006 was synthesized as described elsewhere.³

RNA Interference (RNAi).
Cells were seeded at 2.5 x 10³ cells/35-mm well the day before transfection. Cells were transfected in 1 ml of OPTIMEM with 6 µl of 20 µM B-RAF-specific (5'-AAGUGGCAUGGUGAUGUGGCA-3'), C-RAF-specific (5'-AAUAGUUCAGCAGUUUGGCUA-3'), or control scrambled small interfering RNA (siRNA) (5'-AAGUCCAUGGUGACAGGAGAC-3') using LipofectAMINE (Gibco). After a 5-h incubation with the RNA-complex, 1 ml of medium containing FCS was added. Cells were harvested at the indicated times after the transfection. For DNA synthesis measurements after siRNA treatment, cells were incubated with [³H]thymidine from 92 to 96 h after the addition of siRNA.

In Vivo Studies.
Female CD1 nude mice (Charles River United Kingdom) weighing 19–32 g were used. Cell suspensions were inoculated s.c. in a volume of 0.2 ml into age-matched mice to give groups of seven mice; each mouse received injection with 1 x 10⁷ cells of either ^WTB-RAF- or ^V599EB-RAF-expressing melan-a cells (clones B2 and VE11, respectively). Experiments were conducted in accordance with the United Kingdom Home Office regulations and United Kingdom Coordinating Committee on Cancer Research Guidelines (17) .

	Results

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
We generated melan-a cell lines expressing myc epitope-tagged ^WTB-RAF or ^V599EB-RAF, and, as a control, we generated a cell line (pM4) that only expresses the neo^R gene. Western blotting for the myc tag was used to identify cell lines expressing exogenous B-RAF, and the levels of expression were compared with endogenous protein by blotting for total B-RAF protein. Exogenous ^WTB-RAF was highly expressed compared with endogenous B-RAF in some but not all of the cell lines (B2, B7, B9, and B10), whereas ^V599EB-RAF was consistently expressed at low levels that did not significantly alter the total levels of B-RAF in these cells (VE11, VE14, and VE16; Fig. 1A ). The lack of melanocyte lines expressing high levels of ^V599EB-RAF protein suggests that these cells do not tolerate high B-RAF activity, presumably because it stimulates excessively high levels of ERK activity (see below). Despite the low levels of expression, all of the lines expressing ^V599EB-RAF had constitutive MEK and ERK activation as revealed by Western blotting with antibodies that only bind to the dually phosphorylated, active forms of these proteins (Fig. 1A) . By contrast, even the lines expressing the highest levels of ^WTB-RAF did not have increased MEK or ERK phosphorylation (Fig. 1A) . Thus, overexpression of ^WTB-RAF is not sufficient to trigger constitutive MEK/ERK signaling in melanocytes, whereas even low levels of ^V599EB-RAF stimulate constitutive signaling through this pathway.

View larger version (34K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. V599EB-RAF induces constitutive mitogen activated ERK-activating kinase (MEK) and extracellular signal-regulated kinase (ERK) phosphorylation and mediates 12-O-tetradecanoylphorbol-13-acetate (TPA)-independent growth in melanocytes. A, expression of B-RAF and activation of MEK and ERK. Parental melan-a cells, the control pM4 line, and melan-a clones expressing WTB-RAF (B2, B7, B9, and B10) or V599EB-RAF (VE11, VE14, and VE16) were probed for myc-tagged WTB-RAF, myc-tagged V599EB-RAF, total B-RAF, phospho-MEK, phospho-ERK, total MEK, or total ERK2. B, effects of TPA on ERK activity. Melan-a, pM4, B9, and VE11 cells were cultured in medium lacking TPA for 24 h and then stimulated with 200 nM TPA for the indicated times and analyzed for phospho-ERK and total ERK. Data shown are for one clone expressing WTB-RAF and one clone expressing V599EB-RAF, but similar results were obtained with three independent clones in each case. C, cell proliferation. The melan-a cells, pM4 cells , and the clones indicated were cultured in the presence or absence of 200 nM TPA, and cells were counted after 3 days. The fold increase in growth is shown.

The parental melan-a cells, the pM4 vector controls, and the clones expressing ^WTB-RAF did not grow in soft agar. By contrast, melan-a derivatives expressing ^V599EB-RAF, oncogenic RAS (LTRras cells; Ref. 12 ), and activated versions of MEK (MEKEE cells) all formed colonies in soft agar (Fig. 2, A and B) . Previous studies have established that melan-a cells do not grow as tumors in nude mice (14) , and melan-a cells expressing ^WTB-RAF also failed to grow in nude mice (Fig. 2C) . By contrast, ^V599EB-RAF-expressing melan-a cells did grow as tumors in nude mice (Fig. 2C) .

View larger version (32K): [in this window] [in a new window] [Download PPT slide]   Fig. 2. V599EB-RAF transforms melan-a cells. A, colony formation in soft agar. Quantification of colonies formed in soft agar for melan-a cells and the cell lines pM4, B2, B7, B9, VE11, VE14, VE16, LTRras, and MEKEE. B, morphology of soft agar colonies. Photographs are presented to show the morphology of cells grown in soft agar for melan-a, pM4, B2, B9, VE11, and LTRras cells. C, tumor formation in nude mice. Volumes are shown for tumors formed by inoculation of 1 x 107 VE11 or B2 cells as indicated.

View larger version (40K): [in this window] [in a new window] [Download PPT slide]   Fig. 3. V599EB-RAF-induced proliferation is dependent on MEK-extracellular signal-regulated kinase (ERK) signaling. A, ERK activity. Western blot of phospho-ERK or total ERK from VE11 or LTRras cells treated with U0126 (10 µM), BAY43-9006 (10 µM), or DMSO vehicle for the times indicated. Similar results were obtained with all three V599EB-RAF-expressing clones. B, DNA proliferation. [3H]Thymidine incorporation in VE11 and LTRras cells treated with U0126 (10 µM) or BAY43-9006 (10 µM) compared with the DMSO vehicle control, which was set 100%. Results obtained are the average of three independent determinations (error bars represent SDs from the mean), and similar results were obtained with all three V599EB-RAF-expressing clones. P for each value is 0.0002.

View larger version (55K): [in this window] [in a new window] [Download PPT slide]   Fig. 4. B-RAF is not required for oncogenic RAS-induced melanocyte proliferation. A, MEK and extracellular signal-regulated kinase (ERK) activation. Western blot showing levels of B-RAF, C-RAF, phospho-MEK, phospho-ERK, and total ERK in VE11 and LTRras cells treated with a siRNA to B-RAF, C-RAF, or a scrambled control (sc) for 72 h as indicated. Similar results were obtained with all three V599EB-RAF-expressing clones. B, DNA synthesis. [3H]Thymidine incorporation into VE11 or LTRras cells treated with siRNA to B-RAF or C-RAF compared with the scrambled control, which was set 100%. Results shown are the average of three independent determinations (error bars represent SDs from the mean); Ps are indicated. Similar results were obtained with all three V599EB-RAF-expressing clones. C and D, ERK activation in melanoma cell lines. C, CHL or WM35 cells were transfected with WTB-RAF or V599EB-RAF expression constructs or with vector control and Western blotted for the myc-tagged B-RAF proteins, phospho-ERK, or total ERK2 as indicated. D, WM266-4 or SK-MEL-2 cells were treated with a B-RAF- or C-RAF-specific siRNA or with a scrambled control (sc) as indicated. The cell extracts were blotted for total B-RAF, total C-RAF, total MEK, total ERK, phospho-MEK, and phospho-ERK as indicated.

	Discussion

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 
We have shown that ^V599EB-RAF is an important oncogene that can transform melan-a cells. Clearly, ^V599EB-RAF is not sufficient to induce melanoma because B-RAF is mutated in a high proportion of nevi (6 , 8) . It has been suggested that the melanocytes in nevi are senescent (4) , and it is interesting to note that melan-a cells do not appear to tolerate a high level of B-RAF signaling because all of our ^V599EB-RAF-expressing clones expressed the exogenous gene at very low levels compared with ^WTB-RAF. Nevertheless, even low levels of ^V599EB-RAF transform melan-a cells, possibly because these cells do not express either p16^INK4A or p19^ARF (20) and thus presumably are unable to enter ERK-induced senescence. Reintroduction of p16^INK4A into ^V599EB-RAF-transformed melanocytes did not revert the transformed phenotype because the p16^INK4A did not enter the nucleus and accumulated in the cytosol (data not shown). Additional experiments are currently underway to address how p16^INK4A and ^V599EB-RAF cooperate to induce melanocyte transformation and why p16^INK4A accumulates in the cytosol.

Despite these limitations, the demonstration that melan-a cells can be transformed by ^V599EB-RAF has enabled us to monitor the early changes that lead to pigment cell transformation. ^V599EB-RAF induced constitutive ERK activation that is essential for proliferation, as demonstrated by the use of the MEK inhibitor U0126. ^V599EB-RAF also overcame the need for TPA, an essential melanocyte mitogen (14) that induces strong and sustained ERK activity in melan-a cells (Fig. 1) . These data suggest that ^V599EB-RAF is able to replace TPA in the growth medium because of its ability to stimulate constitutive ERK signaling. Importantly, our data show that C-RAF is not required for MEK/ERK activation or proliferation of ^V599EB-RAF-transformed melanocytes or in melanoma cells harboring oncogenic B-RAF. This is in agreement with the recent finding that C-RAF is not required for MEK activation or transformation of WM793 cells, another melanoma line that expresses ^V599EB-RAF (21) . Despite its important role as an oncogene in melanocytes and melanoma, B-RAF is not required for signaling to ERK in RAS-transformed melanocytes or melanoma cells harboring oncogenic RAS. Similarly, C-RAF depletion failed to block MEK/ERK activity and cell cycle progression in oncogenic RAS-expressing melanocytes. However, RAF-MEK-ERK signaling is clearly required for proliferation of both the RAS and the RAF-transformed melanocytes because the RAF inhibitor BAY43-9006 and the MEK inhibitor U0126 blocked the elevated ERK activity in these cells and also blocked their cell cycle progression. Thus, cells that express oncogenic RAS do not require B-RAF to couple signals to MEK because they can route these signals through the other RAF isoforms.

In summary, our results show that B-RAF can act as a potent oncogene in early stages of melanoma development, whereas ^WTB-RAF is not required for RAS-induced pigment cell transformation, findings that have important implications for future therapeutic strategies.

	ACKNOWLEDGMENTS

 
We thank Prof. D. Bennett (St Georges Hospital, London, United Kingdom) for providing the melan-a cells and Dr. C. Goding for the WM35 cells and the LTRras and MEKEE melanocyte lines.

	FOOTNOTES

 
Grant support: Cancer Research UK, and The Institute of Cancer Research, The Biotechnology and Biological Sciences Research Council Grant 353/C14718.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Richard Marais, Signal Transduction Team, The Institute of Cancer Research 237 Fulham Road, London SW3 6JB, United Kingdom. Phone/fax: 44-20-7153-5171; E-mail: richard.marais{at}icr.ac.uk

³ P. T. C. Wan, M. J. Garnett, M. S. Roe, S. Lee, D. Niculescu-Duvaz, V. M. Good, Cancer Genome Project, C. M. Jones, C. J. Marshall, C. J. Springer, D. Barford, R. Marais. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; in press.

Received 11/ 3/03. Revised 1/15/04. Accepted 2/ 5/04.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results Discussion REFERENCES

 

1. van Elsas A, Zerp SF, van der Flier S, et al Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol, 149: 883-93, 1996.[Abstract]
2. Tsao H, Zhang X, Fowlkes K, Haluska FG Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res, 60: 1800-4, 2000.[Abstract/Free Full Text]
3. Chin L, Pomerantz J, Polsky D, et al Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev, 11: 2822-34, 1997.[Abstract/Free Full Text]
4. Bennett DC Human melanocyte senescence and melanoma susceptibility genes. Oncogene, 22: 3063-9, 2003.[CrossRef][Medline]
5. Davies H, Bignell GR, Cox C, et al Mutations of the BRAF gene in human cancer. Nature (Lond), 417: 949-54, 2002.[CrossRef][Medline]
6. Pollock PM, Harper UL, Hansen KS, et al High frequency of BRAF mutations in nevi. Nat Genet, 33: 19-20, 2003.[CrossRef][Medline]
7. Satyamoorthy K, Li G, Gerrero MR, et al Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res, 63: 756-9, 2003.[Abstract/Free Full Text]
8. Dong J, Phelps RG, Qiao R, et al BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res, 63: 3883-5, 2003.[Abstract/Free Full Text]
9. Bohm M, Moellmann G, Cheng E, et al Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ, 6: 291-302, 1995.[Abstract]
10. Imokawa G, Kobayasi T, Miyagishi M Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes. Cross-talk via trans-activation of the tyrosine kinase c-kit receptor. J Biol Chem, 275: 33321-8, 2000.[Abstract/Free Full Text]
11. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J Biol Chem, 277: 6443-54, 2002.[Abstract/Free Full Text]
12. Wilson RE, Dooley TP, Hart IR Induction of tumorigenicity and lack of in vitro growth requirement for 12-O-tetradecanoylphorbol-13-acetate by transfection of murine melanocytes with v-Ha-ras. Cancer Res, 49: 711-6, 1989.[Abstract/Free Full Text]
13. Albino AP, Sozzi G, Nanus DM, Jhanwar SC, Houghton AN Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. Oncogene, 7: 2315-21, 1992.[Medline]
14. Bennett DC, Cooper PJ, Hart IR A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer, 39: 414-8, 1987.[Medline]
15. Evan GI, Lewis GK, Ramsay G, Bishop JM Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol, 5: 3610-6, 1985.[Abstract/Free Full Text]
16. Leevers SJ, Marshall CJ Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J, 11: 569-74, 1992.[Medline]
17. Workman P, Twentyman P, Balkwill F, et al United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (ed. 2). Br J Cancer, 77: 1-10, 1998.
18. Englaro W, Bertolotto C, Busca R, et al Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem, 273: 9966-70, 1998.[Abstract/Free Full Text]
19. Lyons JF, Wilhelm S, Hibner B, Bollag G Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer, 8: 219-25, 2001.[Abstract]
20. Sviderskaya EV, Hill SP, Evans-Whipp TJ, et al p16Ink4a in melanocytes and differentiation. J Natl Cancer Inst (Bethesda), 94: 446-54, 2002.[Abstract/Free Full Text]
21. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res, 63: 5198-202, 2003.[Abstract/Free Full Text]

This article has been cited by other articles:

				A Agaimy, L M Terracciano, S Dirnhofer, L Tornillo, A Foerster, A Hartmann, and M P Bihl V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours J. Clin. Pathol., July 1, 2009; 62(7): 613 - 616. [Abstract] [Full Text] [PDF]

				G. Lefevre, N. Babchia, A. Calipel, F. Mouriaux, A.-M. Faussat, S. Mrzyk, and F. Mascarelli Activation of the FGF2/FGFR1 Autocrine Loop for Cell Proliferation and Survival in Uveal Melanoma Cells Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1047 - 1057. [Abstract] [Full Text] [PDF]

				J. Yang, S. Zaja-Milatovic, Y.-M. Thu, F. Lee, R. Smykla, and A. Richmond Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy Mol. Cancer Ther., March 1, 2009; 8(3): 636 - 647. [Abstract] [Full Text] [PDF]

				C. A. Pratilas, A. J. Hanrahan, E. Halilovic, Y. Persaud, J. Soh, D. Chitale, H. Shigematsu, H. Yamamoto, A. Sawai, M. Janakiraman, et al. Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer Cancer Res., November 15, 2008; 68(22): 9375 - 9383. [Abstract] [Full Text] [PDF]

				J. Leyton, G. Smith, M. Lees, M. Perumal, Q.-d. Nguyen, F. I. Aigbirhio, O. Golovko, Q. He, P. Workman, and E. O. Aboagye Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901 Mol. Cancer Ther., September 1, 2008; 7(9): 3112 - 3121. [Abstract] [Full Text] [PDF]

				Y. Fukuyo, M. Inoue, T. Nakajima, R. Higashikubo, N. T. Horikoshi, C. Hunt, A. Usheva, M. L. Freeman, and N. Horikoshi Oxidative Stress Plays a Critical Role in Inactivating Mutant BRAF by Geldanamycin Derivatives Cancer Res., August 1, 2008; 68(15): 6324 - 6330. [Abstract] [Full Text] [PDF]

				A. Lahoz and A. Hall DLC1: a significant GAP in the cancer genome Genes & Dev., July 1, 2008; 22(13): 1724 - 1730. [Abstract] [Full Text] [PDF]

				M. Cheung, A. Sharma, S. V. Madhunapantula, and G. P. Robertson Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development Cancer Res., May 1, 2008; 68(9): 3429 - 3439. [Abstract] [Full Text] [PDF]

				R. M. Klein, L. S. Spofford, E. V. Abel, A. Ortiz, and A. E. Aplin B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization Mol. Biol. Cell, February 1, 2008; 19(2): 498 - 508. [Abstract] [Full Text] [PDF]

				C. Spittle, M. R. Ward, K. L. Nathanson, P. A. Gimotty, E. Rappaport, M. S. Brose, A. Medina, R. Letrero, M. Herlyn, and R. H. Edwards Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma J. Mol. Diagn., September 1, 2007; 9(4): 464 - 471. [Abstract] [Full Text] [PDF]

				W. Goessling, T. E. North, and L. I. Zon New Waves of Discovery: Modeling Cancer in Zebrafish J. Clin. Oncol., June 10, 2007; 25(17): 2473 - 2479. [Full Text] [PDF]

				D. Liu, Z. Liu, S. Condouris, and M. Xing BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2264 - 2271. [Abstract] [Full Text] [PDF]

				L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]

				J. Yang, W.-H. Pan, G. A. Clawson, and A. Richmond Systemic Targeting Inhibitor of {kappa}B Kinase Inhibits Melanoma Tumor Growth Cancer Res., April 1, 2007; 67(7): 3127 - 3134. [Abstract] [Full Text] [PDF]

				S. Y. Sharp, K. Boxall, M. Rowlands, C. Prodromou, S. M. Roe, A. Maloney, M. Powers, P. A. Clarke, G. Box, S. Sanderson, et al. In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors Cancer Res., March 1, 2007; 67(5): 2206 - 2216. [Abstract] [Full Text] [PDF]

				R. J. Abi-Habib, R. Singh, S. H. Leppla, J. J. Greene, Y. Ding, B. Berghuis, N. S. Duesbery, and A. E. Frankel Systemic Anthrax Lethal Toxin Therapy Produces Regressions of Subcutaneous Human Melanoma Tumors in Athymic Nude Mice Clin. Cancer Res., December 15, 2006; 12(24): 7437 - 7443. [Abstract] [Full Text] [PDF]

				N. Dumaz, R. Hayward, J. Martin, L. Ogilvie, D. Hedley, J. A. Curtin, B. C. Bastian, C. Springer, and R. Marais In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling Cancer Res., October 1, 2006; 66(19): 9483 - 9491. [Abstract] [Full Text] [PDF]

				M. Kono, I. S. Dunn, P. J. Durda, D. Butera, L. B. Rose, T. J. Haggerty, E. M. Benson, and J. T. Kurnick Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression Mol. Cancer Res., October 1, 2006; 4(10): 779 - 792. [Abstract] [Full Text] [PDF]

				A. Sharma, M. A. Tran, S. Liang, A. K. Sharma, S. Amin, C. D. Smith, C. Dong, and G. P. Robertson Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases Cancer Res., August 15, 2006; 66(16): 8200 - 8209. [Abstract] [Full Text] [PDF]

				L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF]

				C. Petti, A. Molla, C. Vegetti, S. Ferrone, A. Anichini, and M. Sensi Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. Cancer Res., July 1, 2006; 66(13): 6503 - 6511. [Abstract] [Full Text] [PDF]

				K. S.M. Smalley, N. K. Haass, P. A. Brafford, M. Lioni, K. T. Flaherty, and M. Herlyn Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Mol. Cancer Ther., May 1, 2006; 5(5): 1136 - 1144. [Abstract] [Full Text] [PDF]

				A. Calipel, F. Mouriaux, A.-L. Glotin, F. Malecaze, A.-M. Faussat, and F. Mascarelli Extracellular Signal-regulated Kinase-dependent Proliferation Is Mediated through the Protein Kinase A/B-Raf Pathway in Human Uveal Melanoma Cells J. Biol. Chem., April 7, 2006; 281(14): 9238 - 9250. [Abstract] [Full Text] [PDF]

				A. Chiloeches and R. Marais Is BRAF the Achilles' Heel of Thyroid Cancer? Clin. Cancer Res., March 15, 2006; 12(6): 1661 - 1664. [Full Text] [PDF]

				Y. Newbatt, S. Burns, R. Hayward, S. Whittaker, R. Kirk, C. Marshall, C. Springer, E. Mcdonald, Cancer Genome Project, R. Marais, et al. Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen J Biomol Screen, March 1, 2006; 11(2): 145 - 154. [Abstract] [PDF]

				V. Balan, D. T. Leicht, J. Zhu, K. Balan, A. Kaplun, V. Singh-Gupta, J. Qin, H. Ruan, M. J. Comb, and G. Tzivion Identification of Novel In Vivo Raf-1 Phosphorylation Sites Mediating Positive Feedback Raf-1 Regulation by Extracellular Signal-regulated Kinase Mol. Biol. Cell, March 1, 2006; 17(3): 1141 - 1153. [Abstract] [Full Text] [PDF]

				O. M. Grbovic, A. D. Basso, A. Sawai, Q. Ye, P. Friedlander, D. Solit, and N. Rosen V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors PNAS, January 3, 2006; 103(1): 57 - 62. [Abstract] [Full Text] [PDF]

				K. Mercer, S. Giblett, S. Green, D. Lloyd, S. DaRocha Dias, M. Plumb, R. Marais, and C. Pritchard Expression of Endogenous Oncogenic V600EB-raf Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts Cancer Res., December 15, 2005; 65(24): 11493 - 11500. [Abstract] [Full Text] [PDF]

				S. da Rocha Dias, F. Friedlos, Y. Light, C. Springer, P. Workman, and R. Marais Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17-Allylamino-17-Demethoxygeldanamycin Cancer Res., December 1, 2005; 65(23): 10686 - 10691. [Abstract] [Full Text] [PDF]

				V. Emuss, M. Garnett, C. Mason, The Cancer Genome Project, and R. Marais Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAF Cancer Res., November 1, 2005; 65(21): 9719 - 9726. [Abstract] [Full Text] [PDF]

				L Zhuang, C S Lee, R A Scolyer, S W McCarthy, A A Palmer, X D Zhang, J F Thompson, L P Bron, and P Hersey Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma J. Clin. Pathol., November 1, 2005; 58(11): 1163 - 1169. [Abstract] [Full Text] [PDF]

				J. Zhu, V. Balan, A. Bronisz, K. Balan, H. Sun, D. T. Leicht, Z. Luo, J. Qin, J. Avruch, and G. Tzivion Identification of Raf-1 S471 as a Novel Phosphorylation Site Critical for Raf-1 and B-Raf Kinase Activities and for MEK Binding Mol. Biol. Cell, October 1, 2005; 16(10): 4733 - 4744. [Abstract] [Full Text] [PDF]

				R. J. Abi-Habib, J. O. Urieto, S. Liu, S. H. Leppla, N. S. Duesbery, and A. E. Frankel BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin Mol. Cancer Ther., September 1, 2005; 4(9): 1303 - 1310. [Abstract] [Full Text] [PDF]

				C. Wellbrock and R. Marais Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation J. Cell Biol., August 29, 2005; 170(5): 703 - 708. [Abstract] [Full Text] [PDF]

				S. Bloethner, B. Chen, K. Hemminki, J. Muller-Berghaus, S. Ugurel, D. Schadendorf, and R. Kumar Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines Carcinogenesis, July 1, 2005; 26(7): 1224 - 1232. [Abstract] [Full Text] [PDF]

				N. H. Tran, X. Wu, and J. A. Frost B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms J. Biol. Chem., April 22, 2005; 280(16): 16244 - 16253. [Abstract] [Full Text] [PDF]

				A. M. Mirza, S. Gysin, N. Malek, K.-i. Nakayama, J. M. Roberts, and M. McMahon Cooperative Regulation of the Cell Division Cycle by the Protein Kinases RAF and AKT Mol. Cell. Biol., December 15, 2004; 24(24): 10868 - 10881. [Abstract] [Full Text] [PDF]

				S. M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, X. Zhang, P. Vincent, M. McHugh, et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Cancer Res., October 1, 2004; 64(19): 7099 - 7109. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wellbrock, C. Articles by Marais, R. Search for Related Content PubMed PubMed Citation Articles by Wellbrock, C. Articles by Marais, R.